Skip to main content
TIBET AIM PHARM. INC. logo

TIBET AIM PHARM. INC. — Investor Relations & Filings

Ticker · 002826 ISIN · CNE100002C39 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,085 across all filing types
Latest filing 2021-04-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002826

About TIBET AIM PHARM. INC.

https://www.emyy.cn

Tibet Aim Pharm. Inc. is a pharmaceutical enterprise focused on the research, development, production, and distribution of medicinal products. The company integrates traditional Tibetan medicine with modern pharmaceutical manufacturing processes to develop a diverse portfolio of treatments. Its core product range typically includes cardiovascular medications, digestive system therapies, and specialized herbal formulations derived from high-altitude botanical sources. Tibet Aim Pharm. Inc. emphasizes the modernization of traditional formulas through rigorous clinical testing and standardized production techniques. The company serves healthcare providers and patients by providing therapeutic solutions that bridge ancient medical knowledge with contemporary scientific standards.

Recent filings

Filing Released Lang Actions
关于续聘会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the reappointment of an accounting firm (Lixin Certified Public Accountants) for auditing the company's 2021 financial statements and other audit services. It details the qualifications, independence, and past performance of the accounting firm and the approval process by the board and audit committee. The document does not contain any actual financial statements or audit reports but is a notice about the appointment of the auditor. The document length is 3698 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information announcement related to auditor appointment, but since it is an announcement about the auditor appointment and not the audit report itself, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about auditor reappointment.
2021-04-27 Chinese
关于调整2019年限制性股票激励计划回购价格的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the adjustment of the repurchase price of a 2019 restricted stock incentive plan by the company 西藏易明西雅医药科技股份有限公司. It details board and supervisory meetings, approvals, legal opinions, and procedural compliance related to the stock incentive plan and its repurchase price adjustment. The document does not contain financial statements or comprehensive financial data but rather focuses on corporate governance and stock incentive plan adjustments. It is not a full annual or interim report, earnings release, or audit report. It is also not a proxy solicitation or voting result announcement. The document is a formal announcement of a corporate action related to stock incentives and repurchase price adjustments, fitting best under Regulatory Filings (RNS) as it does not fit other more specific categories and is a regulatory disclosure of corporate governance matters.
2021-04-27 Chinese
2020年财务决算报告
Annual Report Classification · 95% confidence The document is titled as the "2020 年财务决算报告" (2020 Financial Final Report) of 西藏易明西雅医药科技股份有限公司. It contains detailed audited financial statements including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance. The audit opinion is included, and the report covers the full fiscal year 2020 with comparative data for 2019. The length of the document is over 12,000 characters, indicating it is a full report rather than a brief announcement. The content matches the characteristics of an Annual Report (10-K) as it provides comprehensive financial performance and company activity for the year. Therefore, the document should be classified as an Annual Report (10-K). FY 2020
2021-04-27 Chinese
2021年第一季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2021 First Quarter Report" of 西藏易明西雅医药科技股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data including income statement, balance sheet, cash flow statement, and notes explaining changes in financial figures compared to previous periods. The document length is about 15,000 characters, which is substantial and contains actual financial statements and analysis. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2021
2021-04-27 Chinese
华西证券关于2020年度募集资金存放与使用的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from Huaxi Securities regarding the deposit and use of funds raised by Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd. in 2020. It includes specifics about the raised funds, their allocation, usage, and balance as of December 31, 2020. The document is not a full annual or interim financial report but a specialized audit or verification report on the use of raised capital, including compliance with regulatory requirements. It is not an announcement or a brief summary but a formal verification opinion, which fits the category of an Audit Report / Information (AR). The document length is 2756 characters, which is relatively short but contains substantive content about the audit of fundraising usage, not just an announcement or certification. Therefore, the best classification is AR with high confidence. FY 2020
2021-04-27 Chinese
公司章程（2021年4月修订）
Governance Information Classification · 95% confidence The document is titled "西藏易明西雅医药科技股份有限公司 章程" which translates to "Articles of Association of Tibet Aim Pharm. Inc." dated April 2021. It contains detailed chapters on company organization, shareholder rights, board of directors, management, financial accounting, profit distribution, auditing, and procedures for shareholder meetings. The content is a comprehensive set of corporate governance rules and internal regulations governing the company's structure and operations. It does not contain financial statements, earnings data, or audit opinions as standalone reports. Instead, it is a governance document outlining the company's internal rules and board structure. Therefore, the document fits the category of Governance Information (CGR). The document length (15,000 characters) and detailed content support this classification with high confidence.
2021-04-27 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.